AdipoGen Life Sciences

IDO1 (mouse) (rec.) (His)

CHF 515.00
In stock
AG-40A-0030-C05050 µgCHF 515.00
More Information
Product Details
Synonyms Indoleamine 2,3-dioxygenase 1; IDO; INDO
Product Type Protein
Properties
Source/Host E. coli
Sequence

Mouse IDO1 (aa 1-407) is fused at the C-terminus to a His-tag.

Crossreactivity Mouse
Biological Activity

Specific Activity: >100’000U/mg protein with L-tryptophan as substrate and after addition of 7μM hemin for protein induction. One unit is defined as the amount of enzyme that produces 1nmol of kynurenine per hour.

MW ~40kDa (SDS-PAGE)
Purity ≥90% (SDS-PAGE)
Endotoxin Content <1EU/μg purified protein (LAL test; Lonza).
Concentration 1mg/ml
Formulation Liquid. 0.2μm-filtered solution in 50mM TRIS-Cl, pH 7.4, containing 1mM EDTA.
Other Product Data

UniProt link P28776: Indoleamine 2,3-dioxygenase 1 (mouse)
Note: Heme content was not determined for the end product.

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
For maximum product recovery after thawing, centrifuge the vial before opening the cap.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system’s ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.